Search Results

You are looking at 81 - 90 of 190 items for :

  • "Renal cell carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Guidelines for the Initial Management of Metastatic Brain Tumors: Role of Surgery, Radiosurgery, and Radiation Therapy

Matthew G. Ewend, David E. Morris, Lisa A. Carey, Alim M. Ladha, and Steven Brem

alone for patients with multiple brain metastases . Int J Radiat Oncol Biol Phys 1999 ; 45 : 427 – 434 . 22. Amendola BE Wolf AL Coy SR . Brain metastases in renal cell carcinoma: management with gamma knife radiosurgery . Cancer J 2000

Full access

NCCN News

various phase I, II and III trials including thyroid cancer, non-small cell lung cancer, and advanced renal cell carcinoma. An additional phase II trial in HCC is underway. Pfizer recently announced that the global randomized phase III AXIS 1032 trial (A

Full access

Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma

Enrique Soto-Perez-de-Celis, Pedro N. Aguiar Jr, Mónica L. Cordón, Yanin Chavarri-Guerra, and Gilberto de Lima Lopes Jr

extrapolated QoL data from previously published studies of cabozantinib in renal cell carcinoma (RCC). 14 The QoL utilities of patients taking placebo were obtained from the placebo arm of the RESORCE trial, which studied the use of regorafenib in a similar

Full access

The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids

Neil J. Shah, Michael R. Cook, Tianmin Wu, Shaked Lev-Ari, Matthew J. Blackburn, Michael T. Serzan, Adil Alaoui, Jaeil Ahn, and Michael B. Atkins

restoration of antitumor immunity and cytolysis. Regimens that incorporate ICIs represent the current standard of care in many advanced malignancies, including melanoma, 3 – 5 non–small cell lung cancer (NSCLC), 6 – 8 renal cell carcinoma (RCC), 9 – 11

Full access

NCCN News

factor (VEGF) receptors. The VEGF pathway plays a distinct role in angiogenesis, which is critical in the growth and survival of solid tumors. Positive topline results from a phase III clinical study in advanced renal cell carcinoma have been reported

Full access

Impact of Immunotherapy on the Survival of Patients With Cancer and Brain Metastases

Saber Amin, Michael Baine, Jane Meza, and Chi Lin

of HER2 inhibitors, epidermal growth factor receptor inhibitors, BRAF kinase inhibitors, and tyrosine kinase inhibitors in BMs from breast, non–small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma and thus could be used in individual

Full access

Imatinib Treatment of Lymphangiomatosis (Generalized Lymphatic Anomaly)

Laura J. Libby, Navneet Narula, Helen Fernandes, James F. Gruden, David J. Wolf, and Daniel M. Libby

approved for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma (HCC), and thyroid carcinoma. 9 However, it was discontinued because of skin toxicity and lack of therapeutic effect (persistent chest pain, dyspnea, and hemoptysis

Full access

Novel Approaches to Advanced Breast Cancer: Bevacizumab and Lapatinib

Erica L. Mayer, Nancy U. Lin, and Harold J. Burstein

Tomczak P . Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) [abstract] . J Clin Oncol 2006 ; 24 ( suppl 1 ): Abstract LBA3

Full access

Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy

Nanruoyi Zhou, Maria A. Velez, Dwight Owen, and Aaron E. Lisberg

chemotherapy (NSCLC: KN189), radiation (NSCLC: PACIFIC), or multikinase inhibitors (renal cell carcinoma: KN426). 25 – 27 A better understanding of the diagnosis and management of irAEs would be especially helpful in settings where treatment modalities have

Full access

Targeting PD-L1 After Adjuvant Radiation in Subtotally Resected Primary Pineal Melanoma: A Case Report and Literature Review

Justin Famoso, Gerald Lemole, Srinath Sundararajan, and Baldassarre Stea

of current management strategies. Case Report A 75-year-old white woman with a past medical history of hypertension and hypercholesterolemia and a family history of male breast cancer in a paternal uncle and renal cell carcinoma in a son presented to